Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Research & Development (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Research & Development for 3 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 34.7% to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.4 million, a 32.4% increase, with the full-year FY2024 number at $20.9 million, up 20.16% from a year prior.
  • Research & Development was $4.3 million for Q3 2025 at Mereo BioPharma, down from $5.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.8 million in Q4 2024 to a low of $3.2 million in Q3 2024.
  • A 3-year average of $4.7 million and a median of $4.3 million in 2025 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 83.62% in 2024; the steepest drop was 24.74% in 2024.
  • Mereo BioPharma's Research & Development stood at $4.8 million in 2023, then skyrocketed by 83.62% to $8.8 million in 2024, then plummeted by 51.59% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Research & Development are $4.3 million (Q3 2025), $5.4 million (Q2 2025), and $3.9 million (Q1 2025).